echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Nature: Prospects for the mRNA drug market in 2035

    Nature: Prospects for the mRNA drug market in 2035

    • Last Update: 2021-09-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Rubik's Cube Info

    Author: Shi Bei

    Recently, Nature Reviews Drug Discovery published an article on mRNA drug market analysis, introducing the global mRNA drug distribution companies and R&D progress, and forecasting the mRNA market in 2035


    With the launch and widespread use of the COVID-19 mRNA vaccine, the mRNA technology platform will make a major breakthrough in 2020


    The mRNA drugs currently under development can be divided into three main categories according to their uses and drug types: preventive vaccines, therapeutic vaccines and therapeutic drugs


    mRNA drugs: number of projects, development stage, and treatment direction

    mRNA drugs: number of projects, development stage, and treatment direction

    Among the 31 companies included in the analysis, 77% have at least one mRNA preventive vaccine, 77% have at least one mRNA therapeutic vaccine, and 35% have at least one mRNA therapeutic drug Of companies reached 55%


    Of the 76 preventive vaccines, 22% are used to prevent COVID-19 infection and 77% are used to prevent other infectious diseases; 21% of the 32 therapeutic vaccines are related to cancer; of the 72 mRNA therapeutic drugs, oncology drugs Accounted for 13%, rare disease drugs accounted for 20%, and respiratory disease drugs accounted for 17%


    From the perspective of product development progress, there are already mRNA preventive vaccines approved for marketing or emergency use authorization (EUA) from Pfizer/BioNtech and Moderna respectively


    Market Trend Forecast of mRNA Products

    Market Trend Forecast of mRNA Products

    Higher development success rate (POS) is the advantage of mRNA vaccines over other vaccines


    Taking into account the target population penetration rate, pricing and competition for the main indications, it is estimated that the average global peak sales of preventive mRNA vaccine drugs (products other than the COVID-19 vaccine) are about 800 million US dollars


    Therapeutic vaccines may be a niche space among mRNA drugs, but based on the size of the patient population and the possible dominance of treatment models targeting multiple tumor-associated antigens, such drugs may have huge commercial potential


    If the target population size, competition between different treatment models, pricing, market penetration, and increased risks are taken into account, the average peak sales of personalized cancer vaccine products are about 5 billion US dollars, and the peak sales of single disease products are about 1.


    Therapeutic drugs may be the biggest opportunity among mRNA drugs, involving many indications, but whether mRNA drugs have clinical advantages over other therapies is still unclear, and there are also high clinical risks


    It is expected that therapeutic drugs will account for 10%-30% of mRNA products


    Outlook

    Outlook

    The market size of mRNA products depends on the sales of COVID-19 vaccines in the short term, and is expected to exceed US$50 billion in 2021


    With the introduction of other preventive vaccines and therapeutic vaccine products, the mRNA drug market is expected to start to grow in 2028 and will reach US$23 billion in 2035


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.